Mercury in child vaccines could be responsible for higher autism rates


Home
Despite a considerable amount of anecdotal evidence, the medical fraternity have long denied any link between the MMR innoculation and the sharp rise in the incidences of autism.

However, a growing number of scientists are supporting the theory that a preservative called thiomersal, present in many vaccines, is responsible for impairing the brain development of young children and producing symptoms very similar to those of autism.

Thiomersal has a mercury content of almost 50% - and mercury is well known for its highly toxic effect. While it is not actually present in the MMR vaccine, several groups of American and Swedish academics are looking into the theory that the cumulative effects of other innoculations that do contain thiomersal in conjunction with the ‘trigger’ effect created by the MMR jab could be the reason that certain children have gone on to exhibit the symptoms of autism, with genetic predisposition potentially also being a factor. Because thiomersal also damages the immune system and gastrointestinal tract, hypersensitivity to toxic environmental substances is created. This could also explains why so many cases of bowel disease have been associated with the MMR vaccine.

The US Institute of Medicine is alarmed enough by these theories to call a 2-day meeting on these recently aired theories which is due to take place in July. One of the chemistry professors invited to give a paper - Boyd Haley, from the University of Kentucky - is on record as saying, ’Thiomersal is extremely toxic. The preliminary data is convincing and does indicate that vaccines are the most likely suspect for causing autism‘.

Despite statements given in May and June last year by the European Agency for the Evaluation of Medicinal Products (EMEA) recommending extreme caution in the use of thiomersal in vaccines, at least 10 children’s vaccinations containing this toxic substance are in use today because drug manufacturers are being permitted to use up stocks. Neither of the EMEA statements appeared in the British press. The first cautioned that cumulative exposure to thiomersal could lead to ’a potential cause for concern’. The second advised in no uncertain terms, ‘For vaccination in infants and toddlers, as a precautionary measure it would be prudent to promote the general use of vaccines without thiomersal. Moreover, the use of thiomersal-free vaccines should be recommended for newborns.‘

Powered By Traffic Booster Absolute News Manager Plug-in by Xigla Software

This article has been moved here